LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Design Therapeutics Inc

Uždarymo kaina

10.7 1.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.16

Max

11.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.6M

-18M

Pelnas, tenkantis vienai akcijai

-0.29

Darbuotojai

54

EBITDA

-1.5M

-20M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+85.78% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-135M

665M

Ankstesnė atidarymo kaina

9.28

Ankstesnė uždarymo kaina

10.7

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-10 23:36; UTC

Uždarbis

Correction to Oracle Reports Higher 4Q Profit Article

2026-06-10 23:19; UTC

Karštos akcijos

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026-06-10 23:09; UTC

Pagrindinės rinkos jėgos

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026-06-10 23:04; UTC

Uždarbis

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026-06-10 20:44; UTC

Pagrindinės rinkos jėgos

Caterpillar Raises Quarterly Dividend 8%

2026-06-10 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Should Take No Options Off The Table

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026-06-10 23:47; UTC

Rinkos pokalbiai

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026-06-10 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026-06-10 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026-06-10 23:32; UTC

Rinkos pokalbiai

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026-06-10 23:20; UTC

Rinkos pokalbiai

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026-06-10 22:05; UTC

Rinkos pokalbiai

Correction to Bank of Canada Stays on Hold Market Talk

2026-06-10 21:57; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:52; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:35; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:22; UTC

Uždarbis

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026-06-10 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-10 20:39; UTC

Rinkos pokalbiai
Uždarbis

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026-06-10 20:34; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 20:33; UTC

Uždarbis

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026-06-10 20:33; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2026-06-10 20:33; UTC

Rinkos pokalbiai
Uždarbis

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

85.78% į viršų

12 mėnesių prognozė

Vidutinis 19.6 USD  85.78%

Aukščiausias 22 USD

Žemiausias 15 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat